Tesamorelin vs Sermorelin:
Key differences comparison

Tesamorelin and Sermorelin are both GHRH analogues that act on the same pituitary receptor, so they produce a similar type of growth hormone pulse and aren't typically combined with each other. Ipamorelin is a different type of peptide, a selective ghrelin-receptor agonist, that triggers growth hormone release through a separate pathway. Because Ipamorelin works differently, it's frequently paired with Sermorelin (or with CJC-1295) to produce a larger, more sustained GH pulse than either peptide alone.

For general anti-aging, sleep, and recovery goals, many people find Sermorelin worth it because it's typically cheaper and gentler than Tesamorelin. For visceral fat reduction specifically, Tesamorelin has the stronger clinical evidence and FDA approval behind it, which may justify its higher cost for that particular goal. The better value depends on what result is being researched, not a single universal answer.

Sermorelin is generally the more affordable option, with reported monthly costs commonly ranging from roughly $100 to $800 depending on the compounding pharmacy and dose. Tesamorelin, as an FDA-approved branded pharmaceutical (Egrifta), typically costs more, with reported ranges from roughly $400 to $3,000 a month depending on dose, insurance coverage, and source. Research-grade versions of both sold by peptide vendors are usually priced lower than the pharmacy or clinic versions, though they aren't intended for human use.

Tesamorelin's clinical trials reported injection-site reactions, joint pain, muscle pain, swelling in the extremities, and effects on blood sugar as the most common side effects. Sermorelin is associated with similar but generally milder effects, most often injection-site redness, itching, or mild bruising, along with occasional flushing, headache, or nausea. Neither compound has extensive long-term human safety data outside Tesamorelin's approved clinical use.

Tesamorelin's FDA-approved protocol is 2 mg injected once daily under the skin, typically in the abdomen. Sermorelin is commonly dosed lower, around 300 mcg (0.3 mg) injected once nightly at bedtime, timed to align with the body's natural overnight growth hormone pulse. Both are given as a subcutaneous injection, but Sermorelin's schedule is built around sleep timing while Tesamorelin's is not.

Tesamorelin has the stronger evidence base for fat loss specifically. Its Phase III trials showed reductions of roughly 15-20% in visceral adipose tissue, the deep fat around organs tied to metabolic risk. Sermorelin raises growth hormone and IGF-1 through the same underlying pathway, which is expected to support fat metabolism, but it doesn't have the same body of FDA-reviewed clinical data targeting visceral fat directly, and it's more often studied for sleep and recovery than weight loss.